Skip to main content

Advertisement

Log in

Breast cancer screening in transgender patients: findings from the 2014 BRFSS survey

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

Transgender patients undergoing transitions often receive cross-sex hormonal therapies, placing them at uncertain risk for developing breast cancer. There is limited population-based information about the extent to which transgender patients undergo mammography screening. Our purpose was to determine the extent to which transgender patients undergo mammography screening using nationally representative survey data.

Methods

Transgender participants between ages 40–74 in the 2014 Behavioral Risk Factor Surveillance System survey were included. Proportions undergoing mammography screening in the last year or two years were calculated stratified by age category and transition status [male to female(MtF), female to male(FtM), non-conforming]. For each transition status, predictors of mammography screening were calculated using logistic regression.

Results

220 transgender patients were within 40–74 years old(35% were MtF, 51% were FtM, 14% were non-conforming). 60.0% underwent mammography screening within the last year (MtF—54.5%, FtM—64.3%, non-conforming—58.1%). 74.1% underwent screening within the last two years(MtF—70.1%, FtM—75.9%, non-conforming—77.4%). For all transgender patients, income category (OR 1.16, 0.82–1.64), higher education category (OR 1.09, 0.31–3.86) and health insurance (OR 0.38, 0.10–1.41) were not associated with increased adherence to mammography screening. Transgender patients were comparably likely to undergo mammography screening compared with non-transgender patients (Adjusted OR 0.97, 0.58–1.62).

Conclusions

High proportions of transgender survey respondents undergo mammography screening (57.9–66.1% within the last year, 71.9–74.4% within the last two years) in our sample, proportions comparable to non-transgender survey respondents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2014

  2. Deutsch MB, Buchholz D (2015) Electronic health records and transgender patients—practical recommendations for the collection of gender identity data. J Gen Intern Med 30(6):843–847

    Article  PubMed  PubMed Central  Google Scholar 

  3. Bazzi AR, Whorms DS, King DS, Potter J (2015) Adherence to mammography screening guidelines among transgender persons and sexual minority women. Am J Public Health. 105(11):2356–2358

    Article  PubMed  PubMed Central  Google Scholar 

  4. McPhee SJ, Nguyen TT, Shema SJ et al (2002) Validation of recall of breast and cervical cancer screening by women in an ethnically diverse population. Prev Med 35:463–473

    Article  PubMed  Google Scholar 

  5. Grant JM, Mottet LA, Tanis J, Harrison J, Herman JL, Keisling M (2011) Injustice at every turn: a report of the national transgender discrimination survey. National Center for Transgender Equality and National Gay and Lesbian Task force, Washington, DC

    Google Scholar 

  6. Hubbard RA, O’Meara ES, Henderson LM et al (2016) Multilevel factors associated with long-term adherence to screening mammography in older women in the U.S. Prev Med 89:169–177

    Article  PubMed  PubMed Central  Google Scholar 

  7. Selvin E, Brett KM (2003) Breast and cervical cancer screening: sociodemographic predictors among white, black, and hispanic women. Am J Public Health 93(4):618–623

    Article  PubMed  PubMed Central  Google Scholar 

  8. Travis RC, Key TJ (2003) Oestrogen exposure and breast cancer risk. Breast Cancer Res. 5(5):239–247

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Unger CA (2016) Hormone therapy for transgender patients. Transl Androl Urol. 5(6):877–884

    Article  PubMed  PubMed Central  Google Scholar 

  10. Collaborative Group on Hormonal Factors in Breast Cancer (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 13(11):1141–1151

    Article  PubMed Central  Google Scholar 

  11. Rossouw JE, Anderson GL, Prentice RL et al (2002) Writing Group for the women’s health initiative investigators. risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333

    Article  CAS  PubMed  Google Scholar 

  12. Chlebowski RT, Rohan TE, Manson JE et al (2015) Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women’s health initiative randomized clinical trials. JAMA Oncol. 1(3):296–305

    Article  PubMed  Google Scholar 

  13. Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ (2013) Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med. 10(12):3129–3134

    Article  PubMed  Google Scholar 

  14. Brown GR, Jones KT (2015) Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res Treat 149(1):191–198

    Article  PubMed  Google Scholar 

  15. Makadon HJ, Mayer KH, Potter J, Goldhammer H (2015) Fenway guide to lesbian, gay, bisexual and transgender health, 2nd edn. American College of Physicians, Philadelphia

    Google Scholar 

  16. Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055–1062

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anand Narayan.

Ethics declarations

Funding

No sources of funding were obtained for the performance of this study.

Conflict of interest

Anand Narayan, Lizza Lebron-Zapata and Elizabeth Morris declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. IRB approval was not required as our study utilized publicly available information.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Narayan, A., Lebron-Zapata, L. & Morris, E. Breast cancer screening in transgender patients: findings from the 2014 BRFSS survey. Breast Cancer Res Treat 166, 875–879 (2017). https://doi.org/10.1007/s10549-017-4461-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4461-8

Keywords

Navigation